Extracellular vesicles - A promising avenue for the detection and treatment of infectious diseases?

Fuhrmann, Gregor; Neuer, Anna Lena; Herrmann, Inge K

dc.contributor.author	Fuhrmann, Gregor
dc.contributor.author	Neuer, Anna Lena
dc.contributor.author	Herrmann, Inge K
dc.date.accessioned	2017-05-16T11:07:12Z
dc.date.available	2017-05-16T11:07:12Z
dc.date.issued	2017-04-07
dc.identifier.citation	Extracellular vesicles - A promising avenue for the detection and treatment of infectious diseases? 2017 Eur J Pharm Biopharm	en
dc.identifier.issn	1873-3441
dc.identifier.pmid	28396279
dc.identifier.doi	10.1016/j.ejpb.2017.04.005
dc.identifier.uri	http://hdl.handle.net/10033/620918
dc.description.abstract	Extracellular vesicles (EVs) have gained increasing attention as novel disease biomarkers and as promising therapeutic agents. These cell-derived, phospholipid-based particles are present in many - if not all - physiological fluids. They have been shown to govern several physiological processes, such as cell-cell communication, but also to be involved in pathological conditions, for example tumour progression. In infectious diseases, EVs have been shown to induce host immune responses and to mediate transfer of virulence or resistance factors. Here, we discuss recent developments in using EVs as diagnostic tools for infectious diseases, the development of EV-based vaccines and the use of EVs as potential anti-infective entity. We illustrate how EV-based strategies could open a viable new avenue to tackle current challenges in the field of infections, including barrier penetration and growing resistance to antimicrobials.
dc.language.iso	en	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/4.0/	*
dc.title	Extracellular vesicles - A promising avenue for the detection and treatment of infectious diseases?	en
dc.type	Article	en
dc.contributor.department	Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany.	en
dc.identifier.journal	European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V	en
refterms.dateFOA	2018-04-10T00:00:00Z
html.description.abstract	Extracellular vesicles (EVs) have gained increasing attention as novel disease biomarkers and as promising therapeutic agents. These cell-derived, phospholipid-based particles are present in many - if not all - physiological fluids. They have been shown to govern several physiological processes, such as cell-cell communication, but also to be involved in pathological conditions, for example tumour progression. In infectious diseases, EVs have been shown to induce host immune responses and to mediate transfer of virulence or resistance factors. Here, we discuss recent developments in using EVs as diagnostic tools for infectious diseases, the development of EV-based vaccines and the use of EVs as potential anti-infective entity. We illustrate how EV-based strategies could open a viable new avenue to tackle current challenges in the field of infections, including barrier penetration and growing resistance to antimicrobials.